Copernicus Capital Management’s Arcus Biosciences RCUS Stock Holding History

Copernicus Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$593K	Sell	17,000 -3,000	-15%	-$93.4K	7.18%	8
2021 Q2	$165K	Buy	20,000 +10,000	+100%	+$286K	2.6%	11
2021 Q1	$281K	Buy	+10,000	New	+$348K	4.54%	11
2020 Q4	–	Sell	-171,982	Closed	-$2.95M	–	16
2020 Q3	$2.95M	Buy	171,982 +47,578	+38%	+$1.06M	2.81%	12
2020 Q2	$3.08M	Buy	+124,404	New	+$3.36M	3.37%	12

Other funds holding RCUS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Copernicus Capital Management's RCUS Position: Q3 2021 in Review

Copernicus Capital Management reduced its Arcus Biosciences (RCUS) stake by 15% in Q3 2021, selling an estimated $93.4K and leaving 17,000 shares worth $593K. The position accounts for 7.18% of the portfolio, ranked #8.

Copernicus Capital Management first reported a position in RCUS in Q2 2020 and has held it in 5 quarters since. The position peaked at $3.08M in Q2 2020. 131 funds tracked by Wall St. Rank hold RCUS as of Q3 2021.

Copernicus Capital Management held 17,000 shares of Arcus Biosciences worth $593K as of Q3 2021.
Copernicus Capital Management sold 3,000 Arcus Biosciences shares in Q3 2021, an estimated $93.4K.
Arcus Biosciences made up 7.18% of Copernicus Capital Management's portfolio in Q3 2021, its #8 holding.
Copernicus Capital Management first reported a position in Arcus Biosciences in Q2 2020 and has held it in 5 quarters since.
Copernicus Capital Management's Arcus Biosciences position peaked at $3.08M in Q2 2020.
131 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.